Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
12 Jun 2016
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
Targeted genome editing in haematopoeitic stem cells
A microRNA driver of B-cell leukaemia
Risk adapted therapy for acute myeloid leukaemia
Evaluation of ibrutinib in treatment of CLL with 17p deletion
An overview of MCL from EHA 2016
The value and strategy for incorporating biosimilars Into clinical practice
Checkpoint inhibitor therapy benefits advanced bladder cancer patients
Sequencing analysis with circulating DNA
Consolidative therapy extends PFS for NSCLC patients
Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC
Daratumumab slows progression in refractory multiple myeloma